Results 41 to 50 of about 1,261,208 (309)

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells [PDF]

, 2015
BRAF inhibitors can extend progression-free and overall survival in melanoma patients whose tumors harbor mutations in BRAF. However, the majority of patients eventually develop resistance to these drugs. Here we show that BRAF mutant melanoma cells that
Baenke, Franziska, Chaneton, Barbara, Dhomen, Nathalie, Galbraith, Laura, Girotti, Maria R., Gottlieb, Eyal, Hogan, Kate, Marais, Richard, Martin, Matthew, Smith, Matthew, Tang, Haoran, Van Den Broek, Niels, Viros, Amaya   +12 more
core   +1 more source

The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)

Cancer Cell International, 2021
Purpose An increasing number of studies have reported a significant association between long non-coding RNAs (lncRNAs) dysregulation and pancreatic cancers.
Elahe Seyed Hosseini, Ali Nikkhah, Amir Sotudeh, Marziyeh Alizadeh Zarei, Fatemeh Izadpanah, Hossein Nikzad, Hamed Haddad Kashani   +6 more
doaj   +1 more source

Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. [PDF]

, 2015
The standard of care for newly diagnosed glioblastoma (GBM) is surgery, then radiotherapy (RT) with concurrent temozolomide (TMZ), followed by adjuvant TMZ. We hypothesized patients with low diffusivity measured using apparent diffusion coefficient (ADC)
Chang, Warren, Cloughesy, Timothy F, Ellingson, Benjamin M, Hardy, Anthony J, Harris, Robert J, Lai, Albert, Leu, Kevin, Mody, Reema R, Nghiemphu, Phioanh L, Pope, Whitney B   +9 more
core   +1 more source

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]

, 2016
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan, Burtness, Barbara, Cheng, Jonathan D, Chow, Laura QM, Chung, Hyun Cheol, Dolled-Filhart, Marisa, Eder, Joseph Paul, Geva, Ravit, Gupta, Shilpa, Haddad, Robert, Kang, Hyunseok, Keam, Bhumsuk, Lee, Se-Hoon, Lin, Chia-Chi, Mahipal, Amit, Mehra, Ranee, Meister, Amy, Muro, Kei, Pathiraja, Kumudu, Seiwert, Tanguy Y, Tahara, Makoto, Weiss, Jared   +21 more
core   +2 more sources

Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. [PDF]

, 2011
BACKGROUND: Surgery is an important part of the management of oral cavity cancer with regard to both the removal of the primary tumour and removal of lymph nodes in the neck. Surgery is less frequently used in oropharyngeal cancer.
Bessell, A, Clarkson, JE, Conway, DI, Furness, S, Glenny, A-M, Macluskey, M, Oliver, R, Pavitt, S, Sloan, P, Worthington, HV   +9 more
core   +3 more sources

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients

Breast, 2021
Background: This meta-analysis aimed to test the hypothesis that the HER2-positive metastatic breast cancer (mBC) patients treated with anti-HER2 antibodies in trial intervention arms have a greater prolongation of overall survival (OS) than of ...
I-Chun Chen, Fu-Chang Hu, Ching-Hung Lin, Shu-Min Huang, Dwan-Ying Chang, Ann-Lii Cheng, Yen-Shen Lu   +6 more
doaj   +1 more source

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. [PDF]

, 2013
IntroductionEffective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data
Arena, Francis P, Baselga, José, Burris, Howard A, Cahana, Ayelet, Campone, Mario, Erdkamp, Frans, Feng, Wentao, Gnant, Michael, Harb, Wael A, Hortobagyi, Gabriel N, Lebwohl, David, Melichar, Bohuslav, Noguchi, Shinzaburo, Petrakova, Katarina, Piccart, Martine, Pistilli, Barbara, Pritchard, Kathleen I, Rugo, Hope S, Taran, Tetiana, Yardley, Denise A   +19 more
core   +2 more sources

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. [PDF]

, 2019
BackgroundThis pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.MethodsThe data were pooled from BRIM-2 ...
Ascierto, Paolo A, Dréno, Brigitte, Flaherty, Keith T, Hauschild, Axel, Larkin, James, Lewis, Karl D, McArthur, Grant A, McKenna, Edward, Mun, Yong, Ribas, Antoni, Wongchenko, Matthew, Yan, Yibing, Zhu, Qian   +12 more
core   +2 more sources

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

BMC Cancer, 2021
Background An upgraded understanding of factors (sex/estrogen) associated with survival benefit in advanced colorectal carcinoma (CRC) could improve personalised management and provide innovative insights into anti-tumour mechanisms.
Chunlong Huang, Xiaoyuan Gu, Xianshang Zeng, Baomin Chen, Weiguang Yu, Meiji Chen   +5 more
doaj   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source